report dilut ep revenu compar street
estim respect notabl compani lower floor
stand-alon guidanc rang revenu ebitda wonder manag
leav room account new competit pressur continu believ
visibl multipl expans new entiti current pro forma ebitda
multipl roughli limit given view real question mark regard
sustain cash flow upjohn busi refer report
detail concern regard qualiti myl execut complex
biosimilar reiter neutral rate rais pt owe
slightli higher estim upjohn busi
forma ev/ebitda
assum debt cash
share outstand discount one
year
rational behind wider guidanc rang name lower floor revenu
ebitda take manag made clear modestli lower ebitda
guidanc midpoint versu prior midpoint function
foreign currenc headwind new revenu guidanc rang
versu previou rang account impact good
old-fashion gener portfolio trim ration low- no-margin product
henc minim chang ebitda guidanc midpoint said wonder
manag leav room account new competit pressur hikma
could enter gener advair market tougher expect competit
landscap regard biosimilar disappoint contribut recent
launch herceptin biosimilar known ogivri mute share gain fulphila due
crowd competit landscap
activ biosimilar pipelin ye commerci execut sure
regard fulphila share underli monthli pegfilgrastim market sale
decemb stood per iqvia product month data
contrast coheru cover udenyca account monthli sale
month avail data manag cite suppli constraint
resolv late would keep mind novarti ziextenzo enter
pegfilgrastim market novemb regard ogivri recal launch
market four approv biosimilar specif ogivri second
herceptin biosimilar mg dose enter market amgen kanjinti launch
juli avail mg mg dose believ fair wonder
fare ogivri given first-to-market particularli consid
fare well fulphila despit advantag
first-to-market suspect lower floor revenu guidanc
debt total capit
risk includ pricing/competit risk generics/biosimilars/matur brand
one world lead gener drug compani
piper sandler seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
mylan actual versu psc consensu estim
consensu estim
compani report factset psc research
consensu
compani report factset psc research
page
million except per psc estimatesstreet estimatesnorth gener administr million except per priorcurr priorcurr priorcurr priorcurr priorcurr priornorth revenuetot gener administr margin tax exhibit
compani report factset psc estim
summari forma viatri estim
compani report factset psc estim
page
priorcurr psc except per tax share million except per priorcurr priorcurr priorcurr priorcurr priormylannorth brand gener margin gener administr margin tax viatri quarterli annual incom statement
million except ep
rest world
sale
sell gener administr
incom loss tax
expens revenu
sell gener administr
sell gener administr
includ shift meridian subsidiari mylan-japan biopharma segment upjohn
proprietari piper sandler februari
current disclosur inform compani found http //www pipersandl com/researchdisclosur
page
 quarterli annual incom statement
million except ep
rest world
sale
sell gener administr
incom loss tax
expens revenu
sell gener administr
sell gener administr
proprietari piper sandler februari
current disclosur inform compani found http //www pipersandl com/researchdisclosur
